



September 3, 2020

Via EDGAR

Securities and Exchange Commission  
Division of Corporation Finance  
100 F Street, N.E.  
Washington, D.C. 20549

**Re: Assembly Biosciences, Inc.  
Registration Statement on Form S-3  
Filed August 28, 2020  
File No. 333-248469  
Request for Acceleration of Effective Date**

Ladies and Gentlemen:

Pursuant to Rule 461 of the Securities Act of 1933, as amended, Assembly Biosciences, Inc. (the "Company") hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-248469) (the "Registration Statement") to 4:00 p.m. Eastern Time on Friday, September 4, 2020 or as soon thereafter as practicable.

The Company acknowledges that both the Company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff of the U.S. Securities and Exchange Commission.

Please contact P. Michelle Gasaway of Skadden, Arps, Slate, Meagher & Flom LLP, special counsel to the Company, at +1.213.687.5122, as soon as the Registration Statement has been declared effective, or if you have any other questions or concerns regarding this matter.

Regards,

By: /s/ Jason A. Okazaki  
Name: Jason A. Okazaki  
Title: Chief Legal and Business Officer

cc: P. Michelle Gasaway  
*Skadden, Arps, Slate, Meagher & Flom LLP*  
Thomas J. Russo  
*Assembly Biosciences, Inc.*  
John O. Gunderson  
*Assembly Biosciences, Inc.*

331 Oyster Point Blvd., 4th Floor, South San Francisco, CA 94080 | [www.assemblybio.com](http://www.assemblybio.com)